Based primarily on studies in the mouse, it has been postulated that at least two separate lineages of B cells exist (reviewed in reference 1). The first lineage, characterized by the cell surface expression of the Ly-1 antigen, appears to be primarily responsible for the secretion of antibodies that display extensive autoreactivity. The second lineage, characterized by the lack of Ly-1 expression, is primarily responsible for the production of "conventional", non-self-reactive antibodies (2-5). This distinction has been most convincingly demonstrated in inbred strains of mice with a genetic predisposition for the development of various autoimmune syndromes (6, 7).The human counterpart ofthe Ly-1 antigen, recently termed CD5, was originally defined using the anti-Leu-1 mAb (8). In this (8) and subsequent (9-12) studies, it was demonstrated that the expanded monoclonal population of B cells that develops in patients with chronic lymphocytic leukemia (CLL)' expresses the CD5 molecule. Thus, CLL appears to represent a clonal overexpansion of the putative autoantibody-producing B lymphocyte . In support ofthis notion are the clinical observations that the sera of patients with CLL occasionally contain autoantibodies and that -20% of such patients develop autoimmune phenomena such as hemolytic anemia (13).On the basis of these findings, the following prospective studies were performed to determine, at the clonal level, if the C135-expressing B cells in patients with CLL and other CD5' B lymphoproliferative disorders secrete mAbs reactive with autoantigens . These in vitro studies demonstrate that leukemic cells from >50% of patients with overexpansions of CD5' cells synthesize and can be made to secrete Ig that is autoreactive . Considering that these secreted mAbs were screened for reactivity with only a limited panel of autoantigens, it is conceivable that an even higher